TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03527836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine brachial plexus block
Description: Combined Axillary-supraclavicular approach to brachial plexus with lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine brachial plexus block
Description: Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixture brachial plexus block
Description: Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
Study: NCT04368741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SANZ®KINGWILL
Description: 20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: GLUCERNA SR®
Description: 17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
Study: NCT02055742

Intervention type: DEVICE
Intervention: illumigene CT and NG assays, illumipro-10
Study: NCT03445364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of different injection pressure during primary PCI
Description: Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of different injection pressure during primary PCI
Description: Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
Study: NCT01507935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk
Description: Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk
Description: Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk
Description: Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
Study: NCT01368744

Intervention type: DEVICE
Intervention: OSNA Breast Cancer System
Description: For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Groups: OSNA Breast Cancer System
Study: NCT00976651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: 200 IU per day in the late follicular phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: 200 IU per day in the late follicular phase
Study: NCT02267902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Study: NCT02661386

Intervention type: DEVICE
Group type: OTHER
Intervention: Motility Procedure
Description: The use of esophageal manometry device during general anesthesia
Study: NCT03102827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ambient air without high-flow therapy administered during first night
Study: NCT02819258

Intervention type: OTHER
Group type: OTHER
Intervention: Endodontic treatment
Study: NCT04116983

Intervention type: DEVICE
Intervention: Deep Ensemble for the Recognition of Malignancy (DERM)
Description: An AI-based diagnosis support tool
Study: NCT03043352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Management of SAM at home
Description: LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Management of SAM at facility
Description: LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
Study: NCT01669252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
Study: NCT02978157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole+amox+levo
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole+bismuth+tetra+levo
Description: esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
Study: NCT01508377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure for PTSD with cognitive restructuring
Description: The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure for PTSD without cognitive restructuring
Description: The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document.
Study: NCT00485758

Intervention type: DRUG
Group type: OTHER
Intervention: ER niacin/laropiprant
Description: One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator : placebo (unspecified)
Description: ER niacin/laropiprant Placebo
Study: NCT03667807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Non invasive brain stimulation
Study: NCT01206972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
Study: NCT03508921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Antibiotics
Description: Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of OnabotulinumtoxinA (BTX-A)
Description: Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
Study: NCT00964769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polysaccharide vaccine
Description: single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
Study: NCT03508921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of OnabotulinumtoxinA (BTX-A)
Description: Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
Study: NCT04048057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.
Study: NCT02077972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole-body infrared heating
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
Study: NCT03217669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablet: 100mg or 300mg
Study: NCT00682760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Botulinum toxin type A (KbtxA) and Botox injection
Description: Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
Study: NCT03716089

Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: Laparoscopic surgery under general anesthesia

Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: Laparoscopic surgery under general anesthesia
Study: NCT03555955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
Study: NCT04728074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Entering Employment and Sustaining Work Program
Description: A structured, motivation and self-awareness based group intervention
Study: NCT00682760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Korean Botulinum toxin type A (KbtxA) and Botox injection
Description: Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
Study: NCT03639688

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Threading on the left lip commissure
Description: Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
Study: NCT04728074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vocational rehabilitation
Description: An individual based, focused on desired job or occupation, face-to-face intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vocational rehabilitation
Description: An individual based, focused on desired job or occupation, face-to-face intervention
Study: NCT03296241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham control
Study: NCT03639688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Threading on the right lip commmissure
Description: Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
Study: NCT03887975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monoplane Occlusion
Description: Monoplane and lingualized occlusion effect on force distribution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lingualized occlusion
Description: Monoplane and lingualized occlusion effect on force distribution
Study: NCT01341236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different nutrional regimen
Description: compare bolus versus intermittent nutrition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comparison of different feeding regimens
Description: compare intermittent versus bolus nutrition
Study: NCT03817931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic
Description: Tablet taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-3 Agonists, Adrenergic
Description: Tablet taken once daily.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: All subjects have fMRI at baseline and again after 30 days

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: All subjects have fMRI at baseline and again after 30 days

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: All subjects have fMRI at baseline and again after 30 days

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Description: All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Description: All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Description: All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
Study: NCT03739060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electric nerve stimulation
Description: Conventional transcutaneous electric nerve stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electric nerve stimulation
Description: Conventional transcutaneous electric nerve stimulation
Study: NCT04255368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-soluble choline
Description: 600 mg choline as choline bitartrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-soluble choline
Description: 600 mg choline as phosphatidylcholine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No choline control
Description: No choline
Study: NCT03211104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01855490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study: NCT02355925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrauterine injection of uhCG
Description: 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study: NCT03667807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Non invasive brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Non invasive brain stimulation
Study: NCT03032211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implant Alfapump® System
Study: NCT02013557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message reminder
Study: NCT00211354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate
Description: ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
Study: NCT02355925

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
Study: NCT01675856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urgent endoscopy
Description: Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Early endoscopy
Description: Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital